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Management of osteoporosis in Hong Kong
MEDICAL PRACTICE
Introduction
Osteoporosis is characterised by low bone mineral
density and the microarchitectural deterioration of bony
tissue with a consequent increase in fracture risk.
The public health impact of osteoporosis stems from
its association with fractures of the hip, spine, and
forearm. Between 10% and 20% of hip fracture patients
die within 1 year of the event, and of those who survive,
almost two thirds remain disabled. The medical cost of
Clinical management guidelines for osteoporosis in
Hong Kong
The Working Group for Formulating Clinical Management Guidelines for Osteoporosis in
Hong Kong
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osteoporosis and its attendant fractures have been placed
at US$5.2 billion (HK$40 billion) each year in the United
States and £615 million (HK$8.0 billion) each year in
the United Kingdom. The total cost for the treatment of
hip fracture in Hong Kong was HK$150 million in 1995.
Epidemiology
Hip fracture incidence from the 1960s to the 1980s
In the 1960s, there was a pronounced geographical
variation in hip fracture incidence, with rates being
much higher in Caucasians living in Northern Europe
and North America than they were in the Hong Kong
Chinese population (Table 1). At that time, the age-
adjusted incidence of hip fracture in the Hong Kong
Chinese population was approximately 13% to 30% of
that observed in Caucasians. With the recent socio-
economic developments, however, the incidence of hip
fracture among Hong Kong Chinese people has increased
by more than two-fold in the past two decades (Table 2).
Currently, the incidence of hip fracture in mainland
China is one of the lowest in the world, being 10 per
10 000 in both men and women. However, there is
some evidence of an increase from 1988 to 1992. The
experience in Hong Kong suggests that with the current
socio-economic development in China, the incidence
of hip fracture is likely to rise rapidly in the future.
Recent hip fracture incidence: from the 1980s to
the 1990s
Recent studies indicate that the age-specific incidence
of hip fracture in the Hong Kong population levelled
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off from 1985 to 1991 in both men and women. The
details are shown in Table 2. Between 1995 and 1996,
the incidence of hip fracture was 11 per 1000 and 5 per
1000 in women and men aged ≥70 years, respectively.
Future hip fracture figures
The projected number of hip fractures in Hong Kong
in the future can be calculated by applying the current
age-specific rates to the future population size of Hong
Kong. Assuming no increase in age-specific rates, the
total numbers for hip fracture in the year 2015 will be
5293 in women and 2349 in men, respectively.
Prevalence of vertebral fracture
Using a definition of vertebral height ratio reduction
by three standard deviations or more, prevalence of
vertebral fracture has been found to be 30% in Hong
Kong women and 17% in Hong Kong men aged 70 to
79 years. These rates are much higher than those found
in Taiwan and mainland China, and are comparable to
those obtained by American Caucasians.
Diagnosis
Definition
The bone mass can be estimated from the bone mineral
density (BMD), which is measured by the degree of
absorption of radiant waves. Using dual energy X-ray
Table 1. Age-adjusted rate* of hip fracture per 100 000 population for females and males, by ethnic group and
year of study†
Ethnic group Study site Study period No. of females No. of males Female:male ratio
Black California, US 1983-1984 241 153 1.6
Hispanic California, US 1983-1984 219 97 2.3
Asian Hong Kong 1985 389 196 2.0
Hong Kong 1965-1967 179 113 1.6
Tottori, Japan 1986-1987 227 79 2.9
Singapore 1955-1962 83 111 0.7
Caucasian Sweden 1972-1981 730 581 1.3
Oxford, UK 1983 603 114 5.3
California, US 1983-1984 617 215 2.9
* Rates were age- and gender-adjusted to the 1990 United States non-Hispanic Caucasian population†
 Table reproduced from Villa ML, Melson L. Race, ethnicity and osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis.
Boston: Academic Press, 1996
Table 2. Age-specific hip fracture rates for three different decades in Hong Kong people (per 100 000 population)*
Age group (years) Men Women
1966 1985 1991 1966 1985 1991
40-49     6     13       9     7     11       6
50-59   16     28     27   22     32     26
60-69   67     54     73   54†   135   112
70-79 224   339   321 173†   501   581
≥80 321† 1156 1191 716† 1521 1916†
* Table reproduced from Lau EM. In: Christiansen C, Riis B, editors. Proceedings of the Fourth International Symposium on Osteoporosis
and Consensus Development Conference, Hong Kong; 1993 Mar 27-Apr 2; Hong Kong†
 1966 and 1991 rates that are significantly different from the 1985 rates at the P=0.05 probability level
Standard deviation for young adult BMD
Standard deviation for age-matched BMD
absorptiometry (DEXA), the World Health Organizat-
ion defines osteoporosis according to the criteria shown
in Table 3. The criteria use the T-score, which is the
difference of a subject’s BMD from the young adult
mean, normalised to the population standard deviation,
with comparison of the data from same sex and ethnic
group.
T-score =
 
Young adult mean BMD – BMD of the subject
The Z-score is a similar concept to the T-score, but
comparison is made to a healthy age- and sex-matched
population instead of a young normal group.
Z-score =
 
 
Age-matched mean BMD – BMD of the subject
Radiological techniques
Techniques for measuring BMD include radiographic
absorptiometry, single/dual photon absorptiometry
(SPA/DPA), single energy X-ray absorptiometry,
DEXA, quantitative single or dual energy computed
tomography (QCT), and quantitative ultrasonography
(QUS). Radiographic absorptiometry evaluates bone
mass at the metacarpals and phalanges quantitatively
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by obtaining a radiograph of the hand. However,
this method is seldom employed due to the lack of
information confirming its accuracy and precision.
The isotope-based DPA technology has been largely
replaced by the X-ray–based DEXA owing to the
higher precision, better image resolution, shorter
scanning time, and reduced radiation dose of the latter
system. A plain radiograph of the spine or other part
of the body is not a method of choice for diagnosing
osteoporosis because it is inaccurate in assessing bone
mineral content. But the appearance of osteopenia on
a radiograph reported by a radiologist is a common
reason for conducting further assessment.
Dual energy X-ray absorptiometry
The current method of choice is DEXA, because it is
fast, precise, and has a relatively low absorptive dose
(2.6-34 µSv depending on the machine, in comparison
with 1 day’s natural background radiation of 10 µSv).
With DEXA, BMD is expressed as g/cm2. BMD
measurements from DEXA machines of different
manufacturers are not directly comparable. BMD is
usually measured at the spine and hip. To detect early
bone loss, the BMD of the spine should be measured.
For the spine, the postero-anterior view is used, but if
there are degenerative changes with osteophytes, a
lateral view is useful.
Quantitative computed tomography
Quantitative computed tomography is useful because
it can selectively measure trabecular bone. It is helpful
when investigating degenerative diseases and defor-
mities of the spine, and in follow-up studies to assess
the response to a treatment. With faster scanners and
more accurate phantoms, the precision of QCT has
been much improved. However, the radiation dose
(60 µSv) is higher than that associated with DEXA.
Quantitative ultrasonography
Quantitative ultrasonography is gaining popularity as
a portable, simple, and cheap technique that does not
involve ionising radiation. The machine measures
the broad-band ultrasound attenuation and speed of
the sound as the sound wave passes through the
bone. Data shows that QUS indices at the heel cor-
relate strongly with BMD at the heel and other sites.
At present, there is no consensus on the use of QUS.
The machine is currently being evaluated as a pri-
mary test for assessing the bone status of a patient.
The precision of this technology is much lower when
compared with the DEXA machine and the use of QUS
in the monitoring of response to treatment remains
under evaluation.
Identifying patients at high risk for the
development of osteoporosis
Osteoporosis is usually asymptomatic until a fracture
occurs and consequently, it is only diagnosed in most
patients after a fracture. There is no convincing evi-
dence of the benefit of population-based screening,
so we should aim for increased awareness to identify
high-risk patients. Case finding is an appropriate
exercise for family physicians to undertake, to diagnose
Table 3. World Health Organization criteria for osteoporosis
Diagnostic category Bone mineral density (BMD) T-score*
Normal A value for BMD within 1 SD of the young adult mean (T-score >-1.0).
Osteopenia A value for BMD more than 1 SD below the young adult mean but less than 2.5 SD
below this value (T-score <-1.0 and >-2.5).
Osteoporosis A value for BMD that is 2.5 SD or more below the young adult mean (T-score <-2.5).
Established osteoporosis A value for BMD that is 2.5 SD or more below the young adult mean (T-score <-2.5)
plus the presence of osteoporotic fracture.
* T-score: standard deviation (SD) of the young adult mean
Box 1. Clinical risk factors for osteoporosis
Constitutional factors:
Caucasian or Asian women
Family history (maternal history of fractures)
Small body frame (BMI <19)
Premature menopause (before age of 40 years) or early menopause (age, 40-45 years)
Lifestyle and nutritional factors:
Smoking
Excessive alcohol intake (more than four standard drinks per day)
Inactivity
Prolonged sedentary periods (eg prolonged bed rest)
Low calcium intake
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the condition before a fracture occurs. Case finding can
begin by identifying patients with clinical risk factors
(Box 1), medical conditions associated with osteoporosis
(Box 2), an X-ray report of osteopenia, and the occurrence
of low-trauma fracture.
The clinical risk factors alone are relatively weak
predictors of osteoporosis, as they apply to a large
sector of the population. The presence of any of the
medical conditions mentioned in Box 2 should be
considered a significant potential risk. Clinicians
should assess the appropriate weighting of different
risk factors in order to efficiently screen patients for
osteoporosis.
Preventing osteoporosis and its related
complications
The Figure shows an algorithm for use in the manage-
ment of osteoporosis.
Calcium
Adequate calcium intake has been shown in numerous
studies to increase BMD during skeletal growth and
to prevent bone loss and osteoporotic fractures in the
elderly. The recommended daily calcium intake for
an adult is 1000 mg. For people who cannot tolerate
milk, calcium can be taken in the form of a calcium
supplement. In general, a 500 mg supplemental calcium
tablet is adequate to prevent excess bone loss. For
adolescents, a higher calcium intake has been shown
to improve the peak bone mass and hence, to reduce
the chance of osteoporosis occurring after menopause.
Vitamin D
Adequate amounts of vitamin D are necessary for
optimal calcium absorption and bone health. Because
there is sufficient sunlight in Hong Kong, it is not
necessary to recommend vitamin D for everyone.
However, for elderly people who are institutionalised
Box 2. Medical conditions associated with an increased risk of osteoporosis
Women with bilateral oophorectomy before normal menopause (age, 45-55 years)
Female hypogonadism lasting more than 6 months before the age of 40 years
Oestrogen-deficient state in premenopausal women (eg anorexia nervosa, excessive exercise leading to
amenorrhoea, hyperprolactinaemia)
Cushing’s syndrome
Hyperthyroidism
Hyperparathyroidism
Chronic liver disease
Chronic renal disease
Malabsorptive disorder
Gastrectomy
Rheumatoid arthritis
Medications: prolonged treatment with oral glucocorticosteroid (ie >3 months), anticonvulsants (phenytoin),
excessive doses of thyroxine
Male hypogonadism
and lack outdoor activities, daily supplementary vita-
min D of 400 to 800 U is recommended.
The value of exercise
Immobility is associated with an increased risk of
osteoporosis and should be avoided in elderly people,
if possible. Regular physical activity is recommended
for all age groups. Regular exercise is also known to
stimulate bone gain and decrease bone loss. The
positive effects of exercise are an adjunct to other
interventions aimed at preventing osteoporosis.
Moderate physical activity in people with osteoporosis
can both improve their fitness and overall quality of
life.
Fall prevention
The consequence of a fall for an osteoporotic individual
would be a fracture. Fall prevention is important for
elderly people who have established osteoporosis.
Exercise programmes for elderly people help to pro-
mote muscle strength and stability.
Any risk factors predisposing the elderly to a fall
should be detected and treated early. Visual impairment
is an important risk factor for a fall, and cataract is the
most common cause of visual impairment in the
elderly. Neurological conditions such as Parkinson’s
disease should be treated promptly to reduce the
chances of a fall because of poor mobility. Iatrogenic
conditions such as postural hypotension due to the
overtreatment of hypertension in the elderly should be
avoided. The use of sedative and hypnotic drugs are
common causes of a fall, so caution should be taken in
prescribing these drugs to the elderly. Housing and
public facilities should be designed so that they are
safe environments.
Elderly people with risk factors for or a known
history of falls should be assessed by physiotherapists
and occupational therapists so that proper muscle
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training and rehabilitation can occur. Walking aids will
be helpful. Hip protectors have been found to be useful
overseas, but they have not been shown to be useful in
Hong Kong.
Drug treatment for osteoporosis
Hormone replacement therapy
Hormone replacement therapy and osteoporosis
prevention
The beneficial effect of oestrogen on bone mass has
been clearly demonstrated in prospective, double-blind,
controlled studies. Several epidemiological studies
have supported a reduction of approximately 50% in
the risk of hip fracture or fracture of the distal radius
with the long-term use of oestrogen. Fewer data are
available to suggest that a reduction in vertebral
fracture risk occurs.
The beneficial effects of oestrogen are greatest
when treatment begins closest to the time of the
meno-pause and with a duration of treatment of at least
5 years. Oestrogen intervention much later in life may
be equally beneficial in preventing osteoporosis, but
bone loss begins again when oestrogen therapy is
discontinued.
Bone densitometry can identify those women at risk
and help with their decision making regarding hormone
replacement therapy (HRT).
Hormone replacement therapy and osteoporosis
treatment
In addition to the prevention of osteoporosis, oestrogen
therapy has been shown in controlled trials to be
beneficial even in patients with established osteo-
porosis. Significant increases in bone mass have been
observed over 12 to 18 months of treatment, the effect
being greatest in the lumbar spine.
Who should receive hormone replacement
therapy?
Hormone replacement therapy should be considered
for all postmenopausal women with established osteo-
porosis or osteopenia, given its proven efficacy in
increasing bone density and decreasing fractures, as
* BMD bone mineral density
†
 HRT hormone replacement therapy
Fig. Algorithm for the management of osteoporosis
Assess risk factors for osteoporosis
Patient with risk factors for
osteoporosis but no fracture
Patient with prior or incidental
low-trauma fracture
Counsel patient about:
• Calcium intake
• Vitamin D intake
• Physical activity
Osteoporosis
BMD* not available BMD measurement
T score
> -1
T score
-1 to -2.5
T score
< -2.5
Normal Osteopenia
Offer HRT for
osteoporosis
prevention
Osteoporosis HRT† is indicated
Patient does
not accept/
contra-indicated
Bisphosphonates
with BMD follow-up
Counsel patient about:
• Calcium intake
• Vitamin D intake
• Physical activity
Patient accepts
Long-term HRT
with BMD follow-up
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well as its additional cardiovascular and quality of life
benefits.
Oestrogen offers benefits not supplied by other
drugs used in the prevention and treatment of osteo-
porosis. The administration of oestrogen reduces the
risk of coronary artery disease by up to 50%, both by
its action on the lipid profile and through a direct effect
on blood flow. Oestrogen also protects against stroke
and increases peripheral blood flow. Recent evidence
suggests that oestrogen protects against Alzheimer’s
disease and may benefit women already suffering from
a mild to moderate degree of this condition. Positive
effects have also been demonstrated on memory, mood,
quality of life, and genito-urinary tract symptoms.
The dosage of oestrogen prescribed specifically
for osteoporosis is critical for its effectiveness. Effec-
tive daily doses of Food and Drug Administration–
approved preparations include conjugated equine
oestrogen 0.625 mg, piperazine oestrone sulphate 0.75
to 1.25 mg, and transdermal oestradiol 50 to 100 µg.
Effective daily doses of other preparations include
micronised oestradiol 0.5 to 1.0 mg and oestradiol val-
erate 1 to 2 mg. Oestrogen can be given by any route of
administration with similar effects.
For patients with a uterus, progestins are added for
at least 10 days per month because cyclic adminis-
tration of progestins abolishes the risk of endometrial
pathologies developing. Continuous combined therapy
is aimed at preventing cyclical bleeding and is more
appropriate for women with an established menopause
who do not wish to have vaginal bleeding. Progestins
do not negate the effect of oestrogen in its action on
bone and some 19-nortestosterone derivatives may
even have an independent beneficial effect.
Contra-indications and precautions regarding the
use of hormone replacement therapy
Contra-indications to the prescribing of oestrogen
replacement include the following: undiagnosed
vaginal bleeding, acute liver disease, chronic impaired
liver function, a recent history of thromboembolism
or thrombophlebitis, and suspected breast or endo-
metrial carcinoma or a past history of these tumours.
Although able to use oestrogen replacement,
caution must be taken in giving it to patients with pre-
existing hypertension, benign disease of the breast,
uterine fibromyoma, pelvic endometriosis, gall bladder
disease, a history of migraine headaches, familial
hyperlipidaemia, and chronic thrombophlebitis. The
final decision regarding the use of oestrogen therapy,
however, should be an individual one, taking into
account the risks/benefits of oestrogen therapy and the
concerns of the user.
Complications of hormone replacement therapy
Endometrial hyperplasia and carcinoma
Postmenopausal women receiving unopposed oestro-
gens have a 3- to 15-fold increased risk of developing
endometrial carcinoma. The risk is correlated with both
the dose and the duration of oestrogen exposure. The
administration of 10 mg medroxyprogesterone acetate
or equivalent for 10 days each month has been shown
to be protective. Consequently, all postmenopausal
women who have not had a hysterectomy should receive
HRT as a combination of oestrogen and progestin.
Breast cancer
Although substantial evidence supports the role of
oestrogen in the genesis of breast cancer, there is no
definite evidence to suggest that the postmenopausal
administration of oestrogen increases the risk of
breast cancer. Epidemiological studies suggest that
oestrogen use does not cause an increased risk of breast
cancer in the first 5 years, but this risk may increase
when there has been 5 years or more of treatment. The
risk is increased in women with a family history of
breast cancer. This theoretical slight increase in the
risk of breast cancer must be balanced against the
benefits of prevention of osteoporosis, cardiovascular
disease, and Alzheimer’s disease.
Management of hormone replacement
therapy
A thorough history should be taken to elicit contra-
indications to the use of HRT. The physical examina-
tion should include a blood pressure reading, breast
and pelvic examinations, and a cervical smear. A
baseline mammogram should also be performed to
exclude subclinical breast cancer. A breast examination
should be performed annually and mammography
conducted at 2-year intervals.
After the commencement of HRT, a follow-up visit
should be arranged for 3 months later to ensure there
are no problems. Further visits should be made at 6- to
12-month intervals. Any abnormal uterine bleeding
must be appropriately investigated and an endometrial
biopsy performed.
Bone antiresorptive agents
Bisphosphonates
Bisphosphonates inhibit bone resorption by binding
to mineralised bone surfaces. These compounds may
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be considered an alternative to HRT in postmenopausal
osteoporotic women who cannot tolerate HRT. Com-
pared with HRT, bisphosphonates are bone specific,
of equal or greater efficiency in improving bone den-
sity, and have fewer side effects. The bisphosphonates
are poorly absorbed and should not be taken with meals
or calcium tablets. Currently, etidronate disodium and
alendronate sodium are the most commonly used bis-
phosphonates. Treatment with these drugs should be
given for 3 to 5 years. It is uncertain how long the drug
should be continued and whether bone loss will resume
once the treatment is stopped. There are ongoing
trials to evaluate the use of bisphosphonates in treating
male osteoporosis and steroid-induced bone loss.
Etidronate
Treatment with etidronate can increase the lumbar
spine BMD by 5% to 10% over 2 years and the verte-
bral fracture risk decreases. The effect of etidronate
on hip fracture is not known. To avoid the minerali-
sation defect, etidronate is given cyclically at a dosage
of 400 mg/d for 14 days every 3 months. Calcium
supplementation is given during the rest of the 3-month
cycle when the patient is not receiving etidronate; side
effects of etidronate treatment are uncommon.
Alendronate
Alendronate given at a dosage of 10 mg/d increases
the lumbar spine BMD by 8% and the femoral neck
BMD by 5% in 3 years. In large randomised controlled
trials, alendronate has been found to reduce both verte-
bral and hip fracture by approximately 50% in post-
menopausal osteoporotic women—in those with and
without pre-existing vertebral fractures. Alendronate
is prescribed at a continuous dosage of 10 mg/d and is
not known to cause inhibition of bone mineralisation.
The drug must be taken with a full glass of water at
least 30 minutes before breakfast. Side effects are
those of upper intestinal and oesophageal irritation.
Calcitonin
Calcitonin inhibits bone resorption by inhibiting
osteoclast activity. Short-term studies of 1 to 2 years’
duration showed significant improvement in BMD in
postmenopausal women. However, long-term effects
of calcitonin on BMD and fracture prevention are
not known. Current evidence does not provide strong
support for the use of calcitonin as a first-line treat-
ment of established osteoporosis. Use is also con-
strained by cost considerations. Calcitonin is given
either as an intramuscular or subcutaneous injection
(50 to 100 U/d or 100 U three times per week) or as a
nasal spray (200 U/d). The available form of calcitonin
in Hong Kong is the salmon calcitonin. When given
parenterally, calcitonin may cause nausea, flushing,
and gastro-intestinal upset, while nasal calcitonin can
result in nasal irritation.
In addition to preventing bone loss, calcitonin also
has an analgesic effect and can reduce the acute pain
associated with vertebral fractures. Therapy should be
adjusted according to response and may be effective
for at least 1 month.
Other therapeutic agents
The following drugs have been used for the treatment
of osteoporosis and are available in Hong Kong:
(1) Fluoride salts (enteric-coated sodium fluoride
20-40 mg/d orally)
(2) Vitamin D derivatives: calcitriol (1,25-dihydroxy-
cholecalciferol, 0.25-0.5 mg/d) and alfacalcidol
(1α-hydroxycholecalciferol, 1 mg/d)
(3) Anabolic steroids (eg stanozolol 5 mg/d orally;
nandrolone decanoate 50 mg intramuscularly,
every 2-4 weeks)
Each of these agents has been shown in some
clinical trials to improve bone mass, but their efficacy
in preventing fractures is not established. The use of
these agents should be restricted to patients who have
failed to respond to conventional therapy and clinicians
who are familiar with their toxic effects.
Monitoring treatment progress
Bone density measurements
For follow-up measurements, repeat BMD measure-
ments by DEXA studies at 2-year intervals are advised.
Even with the best treatment and response, there will
only be 5% to 10% increase in bone density. The BMD
measured on different machines cannot be directly
compared as there are significant differences in the
methods used. Patients should be followed up using
calibrated machines from the same manufacturers.
Biochemical markers of bone turnover
Treatment with antiresorptive agents in postmeno-
pausal osteoporosis induces a 30% to 60% decrease in
biochemical markers of bone turnover within
3 to 6 months of therapy. These include markers of
bone resorption such as urinary pyridinoline and
n-telopeptide and markers of bone formation such as
serum osteocalcin and bone-specific alkaline phos-
phatase. The acute response of the biochemical
markers to the treatment is predictive of the sub-
sequent response of the bone mass over 2 years.
Thus, measurement of biochemical bone markers at
baseline and after 3 months of therapy is likely to be
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helpful in the management of osteoporotic patients,
since treatment effect can be detected before changes
in BMD occur. At present, these biochemical tests
are not widely available.
Management of osteoporotic fractures
Hip fractures
The standard hemi-arthroplasty for femoral neck frac-
tures and dynamic hip screw system (including gamma
nail) for trochanteric fractures should be endorsed.
Early intervention, if the patient’s general condition
allows, is important. Much of the morbidity and
mortality is related to the associated complications.
Special surgical care must be exercised under the
following circumstances: extreme comminution, severe
osteoporosis, wide displacement, and concomitant
illnesses. Special devices (eg gamma nail) or additional
manoeuvres (eg screwing, cementing, osteotomy)
might have to be considered.
While early effective surgery should be the rule,
overenergetic surgery or a ruthless push for surgery
in spite of the patient’s poor general condition is a
well-known contributing factor towards mortality.
The China and Hong Kong experience of conservative
traction giving few complications should be borne
in mind. If surgery cannot be followed by sitting and
standing in 2 to 3 days’ time,  the decision to operate
may not be a wise one. Every patient with a fractured
hip should be considered as a ‘high-risk’ patient and
treated conservatively.
Vertebral fractures
Vertebral fractures, either silent or painful, are probably
the most common fractures that arise in osteoporotic
elderly individuals. Diagnosis is made on clinical
grounds and by imaging studies. Fractures can be of
various types including squashed, anterior-wedged,
or posterior-wedged fractures. Fractures can also
occur in clusters. The most troublesome symptom of
an osteoporotic vertebral fracture is pain. The pain can
be excruciating but controlled by simple analgesics or
non-steroidal anti-inflammatory drugs. Morphine and
other potent analgesics may be required. Calcitonin is
a useful adjunctive analgesic agent. Intercostal blocks
should be considered if there is high-level (thoracic)
involvement. The use of a soft abdominal corset can
also bring relief. A small proportion of vertebral
fractures involve the spinal cord or cause root com-
pression and will require surgical decompression.
Distal radial fracture
The management of a distal radial fracture may present
difficulties because of the loose density and shattering.
The elderly person’s age and low demand prompt
for conservative treatment. However, the difficulty of
holding the fracture ends together and any sub-
sequent deformities cause real suffering. More fre-
quent assessment and supervision could prevent this
problem. Occasionally, a surgically placed bone graft
spacer may have to be considered. In cases of severe
deformity and pain, corrective measures need to be
carried out.
Other treatment
To ensure the comprehensive and efficient rehabili-
tation of these patients, a multidisciplinary approach
in caring for them is crucial. The early involvement of
family members, social workers, and other allied health
professionals should aid in the establishment of a
complete and holistic management scheme for these
individuals. All patients with osteoporotic fractures are
at high risk for the development of further fractures
and should receive active treatment to prevent further
bone loss.
The health care cost of osteoporosis in Hong
Kong
As in all developed countries, the management of
osteoporotic fractures accounts for a significant pro-
portion of the health care cost in our community. With
the continuing ageing of the Hong Kong population,
the number of osteoporotic fractures and the asso-
ciated health care cost will most certainly increase.
The estimated expenditures in the management of
osteoporosis are the following:
(1) Cost of acute care for hip fracture in 1995 = total
number of hip fractures (3783) x estimated acute
care cost for one hip fracture patient (HK$40 000)
= HK$151 million
(2) Estimated cost of acute care for vertebral fracture
in 1995 = number in the population with vertebral
fracture (94 009) x percentage seeking treatment
(1%) x estimated acute care cost for one vertebral
Table 4. Approximate cost of drug treatment in the
management of osteoporosis
Drug Cost per patient
per year (HK$)
Alendronate 4200
Alfacalcidol 1000
Calcitriol 5600
Calcitonin (salmon) 9250
Calcium carbonate 430
Calcium lactate/gluconate 800
Fluoride 1300
Oestrogen-progestin 650
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fracture patient (HK$40 000) = HK$38 million
(3) Cost of screening all postmenopausal women in
Hong Kong = Cost of one BMD measurement by
DEXA (HK$460) x number of postmenopausal
women in Hong Kong (702 000) = HK$323 million
Table 4 shows the approximate cost of the available
drugs for the management of osteoporosis. Current
data indicate that mass screening to detect low BMD
may not be the most cost-effective approach in the
prevention of osteoporosis in Hong Kong.
